Materialise Nv · EURONEXT:MTLS
Materialise Nv — Investor Presentation (June 2024)
32 slides from Materialise Nv's investor presentation, June 2024
Slide 1: Corporate Presentation
Corporate Presentation www.materialise.com | NASDAQ: MTLS June 2024
Slide 2: Safe Harbor Summary
Safe Harbor Summary This pr esentation has been pr epared solely for use at this meeting. By reading or reviewing the pr esentation slides, you agree to be bound by the following limitations. This presentation has been prepared for informational and background purposes only and the information conta
Slide 3: Global software and service platform for 3D printing
Global software and service platform for 3D printing 575+ AM Software Number of patents 3 256M 12% Software Medical Manufacturing Revenue 2023 Adj. EBITDA4 A platform of software tools that Complete end-to-end solutions >200 3D printers worldwide (€mm) margin 2023 manage and control the 3D (visualiz
Slide 4: Empower the choice for sustainability
Empower the choice for sustainability ✓ Strategy ◼ Reduce stock by printing on demand ◼ Reduce transportation by printing de-localized ◼ Reduce material usage by printing first time right and personalized → All while ensuring the reliable, repeatable quality your customers expect ! ✓ Products & solu
Slide 5: Our growth strategy
Our growth strategy General Adaption of AM Meaningful Applications of AM Horizontal Vertical ✓ Consultancy ✓ Medical ✓ Materialise Mindware ✓ CMF ✓ Software platforms ✓ Orthopaedics ✓ Magics / CO-AM ✓ Cardiovascular ✓ Mimics ✓ Respiratory ✓ 3D printing services ✓ Wearables ✓ Prototyping (plastic & m
Slide 6: Materialise Mindware
Materialise Mindware Helping you strategize and implement your AM ambitions Materialise Mindware ✓ Proven experience in building AM businesses ✓ Access to state-of-the-art manufacturing facilities ✓ Advanced software for scaling AM Unique ✓ Multidisciplinary teams (engineering, design, formula for p
Slide 7: Magics Software Platform
Magics Software Platform empowering the choice for AM We Answer Market Needs ✓ Software functionality across major printing OEMs, an Focus on AM Machine: open ecosystem Including import, design, documenting ✓ Integration within the product development cycle and and planning functionality manufacturi
Slide 8: Mimics Innovation and Care Suites
Mimics Innovation and Care Suites empowering the choice for AM Mimics Innovation and Care Suites ✓ Medical 3D-image based engineering software ✓ Offers complete end-to-end solutions: ◼ Segmentation and Visualisation ◼ Planning ◼ Design Application ◼ Printing preparation neutral ◼ Case management ✓ I
Slide 9: One of the world's largest 3D Printing Factories
One of the world’s largest 3D Printing Factories Plastic & 3D Print Factory Metal ✓ Online portal for end parts and prototypes ✓ Certified hub for complex end part manufacturing ✓ Dedicated aerospace, eye- and footwear-printing lines ✓ ~ 185 industrial 3D printers, incl 19 metal printers 9
Slide 10: End-to-end Medical Personalization Platforms
End-to-end Medical Personalization Platforms empowering the choice for meaningful medical applications of AM Personalized Devices (CMF, Ortho, Cardio, Pneumo) ✓ End-to-end platforms for visualizing, designing, customizing, printing, managing and delivering customized medical instruments and implants
Slide 11: End-to-end Fitting Platforms for Wearables
End-to-end Fitting Platforms for Wearables empowering the choice for meaningful wearable applications of AM Materialise Motion (footwear): ✓ Science-based Footscan technology ✓ Collaboration with Superfeet in United States Materialise Eyewear: ✓ Both plastic and metal ✓ Partners include Hoya 11
Slide 12: Financial highlights
Financial highlights 12
Slide 13: Q2 2024 & Full Year 2023 Financial Highlights
Q2 2024 & Full Year 2023 Financial Highlights Q2 2024 Full Year 2023 • Revenue of 68,797 kEUR, representing an increase of 6.2% from • Total revenue increased 10.4% to 256,127 kEUR Q2 2023 • Gross Margin of 145,131 kEUR, representing 56.7% of revenue • Gross Margin of 39,227 kEUR, representing 57.0%
Slide 14: Consolidated Revenue
Q2 2024 & Full Year 2023 Consolidated Revenue Q2 2024 Revenue by Segment 300,000 €256,127 Thousands 250,000 €232,023 16% Software 200,000 Medical 43% 150,000 Manufacturing 100,000 €64,810 €68,797 41% 50,000 0 Q2 2023 Q2 2024 FY 2022 FY 2023 • Revenue of 68,797 kEUR, representing an increase of 6.2%
Slide 15: Consolidated Adjusted EBIT & EBITDA
Q2 2024 & Full Year 2023 Consolidated Adjusted EBIT & EBITDA Adj. EBIT Adj. EBITDA €40,000 €40,000 12.3% Thousands Thousands €35,000 €35,000 €31,397 €30,000 €30,000 8.2% €25,000 €20,000 3.9% €25,000 €15,000 5.6% €20,000 €19,014 € 9,886 13.4% €10,000 €15,000 -0.9% € 3,872 -1.3% €5,000 7.3% €9,188 €10
Slide 16: Medical Segment
Q2 2024 & Full Year 2023 Medical Segment 26.2% €28,000 €26,544 €120,000 Thousands €101,376 Thousands €24,000 22.2% €100,000 €84,846 €18,822 €20,000 €80,000 €16,000 29.1% €60,000 €12,000 10.8% €40,000 €8,199 €28,141 €8,000 €24,945 €20,000 €4,000 €2,683 €0 €0 Q2 2023 Q2 2024 FY 2022 FY 2023 Q2 2023 Q2
Slide 17: Software Segment
Q2 2024 & Full Year 2023 Software Segment €10,000 16.8% Thousands €50,000 €43,688 €44,442 Thousands €8,000 €7,450 €40,000 €6,000 €30,000 17.9% €4,000 12.2% €20,000 3.5% €11,030 €11,226 €1,973 €10,000 €2,000 €1,374 €1,514 €0 €0 Q2 2023 Q2 2024 FY 2022 FY 2023 Q2 2023 Q2 2024 FY 2022 FY 2023 Revenue A
Slide 18: Manufacturing Segment
Q2 2024 & Full Year 2023 Manufacturing Segment €120,000 €110,310 8.0% 6.8% €10,000 Thousands €103,489 Thousands €100,000 €8,229 €7,537 €8,000 €80,000 €6,000 €60,000 9.4% 8.2% €4,000 €40,000 €28,835 €29,429 €2,708 €2,416 €20,000 €2,000 €0 €0 Q2 2023 Q2 2024 FY 2022 FY 2023 Q2 2023 Q2 2024 FY 2022 FY
Slide 19: Income Statement Highlights
Income Statement Highlights Q2 Full Year (in thousands of euros, except where indicated) 2024 2023 2023 2022 Revenue 68,797 64,810 256,127 232,023 Cost of sales (29,570) (27,764) (110,996) (103,255) Gross profit 39,227 37,047 145,131 128,768 Research & development expenses (11,090) (9,489) (38,098)
Slide 20: Other Financial Highlights
Other Financial Highlights (in thousands of euros) 6/30/24 12/31/23 Cash and equivalents 125,492 127,573 Receivables 49,655 52,698 Inventories 17,846 17,034 Payables 23,764 22,973 Deferred income 49,757 51,492 Borrowings 57,968 64,398 Equity 243,140 236,594 Total balance sheet 397,635 396,630 (in th
Slide 21: Fiscal 2024 Financial Guidance Update
Fiscal 2024 Financial Guidance Update • Expect consolidated Revenue to grow to 265 – 275 mEUR • Expect consolidated Adjusted EBIT to be between 11 – 14 mEUR Note: As of 202 4 Materia lise will b e p roviding guidan ce for both con solid ate d r eve nue as well as consolidated Adju sted EBIT an d wil
Slide 22: Appendix
Appendix 22
Slide 23: Adjusted EBIT & EBITDA Reconciliation
Adjusted EBIT & EBITDA Reconciliation For the quarter ended For the year ended June 30 December 31 (in thousands of euros) 2024 2023 2023 2022 Net profit/(loss) 3,875 (494) 6,695 (2,153) Income taxes 959 532 78 975 Financial expenses 1,441 670 3,865 4,420 Financial income (2,474) (1,305) (5,019) (6,
Slide 24: Consolidated Revenue, Adj. EBITDA and Gross margin
2019 - 2023 Consolidated Revenue, Adj. EBITDA and Gross margin Revenue 2019-23 (€mm) Adj. EBITDA1 2019-23 (€mm) Gross margin 2019-23 (%) 6% (13)% 21% 23% 10% 14% 12% 16% 8% 12% 256 232 197 205 56% 55% 58% 55% 57% 170 32 31 27 20 19 2019 2020 2021 2022 2023 2019 2020 2021 2022 2023 2019 2020 2021 202
Slide 25: Revenue and Adj. EBITDA by segment
Revenue and Adj. EBITDA by segment Software Medical Manufacturing 11% (6)% 10% 2% 2% 16% 2% 19% 16% 20% (1)% (26%) 28% 16% 7% 73 85 101 103 110 Revenue (€mm) 62 94 89 61 44 44 70 42 39 43 2019 2020 2021 2022 2023 2019 2020 2021 2022 2023 2019 2020 2021 2022 2023 33% 34% 37% 3% 17% 18% 23% 28% 22% 26
Slide 26: aati |
aati | -. materialise innovators you can count on co-am rd Party Integration 3rd Party Integration an materialise
Slide 27: Diversified go-to-market infrastructure
Diversified go-to-market infrastructure Software Medical Manufacturing Direct OEM Channel Direct Partner Imaging Online Direct Partner Sales Partners Partners Sales Sales Companies Portal Sales Sales 27
Slide 28: Global presence
Global presence @ Office Production Center EH Competence Center AUSTRALIA — -_— materialise
Slide 29: Management team
Management team Other Members of Executive Committee Name Title Johan Pauwels Chief Operating Officer Brigitte de Vet- Bart Van der Schueren Chief Strategy and Technology Officer (CSTO) Veithen CEO Carla Van Steenbergen Vice President - Corporate Affairs Jurgen Laudus Vice President – Manufacturing
Slide 30: Historic and potential growth in additive manufacturing
Historic and potential growth in additive manufacturing Additive manufacturing market forecast ($bn) 85 Manufacturing: $14tn 43 AM Market: $15bn 21 12 15 2019 2021 2023 2027 2031 Sou rce : Wohler 202 2 r eport 30
Slide 31: Unleashing Growth through ACTech Product Offering
Unleashing Growth through ACTech Product Offering Using Additive Manufacturing to Create Choices for Sustainability Stator Housing for Electric Motor Truck Axle Machining of a ¨Printed Wheel Carrier including synthetic core for an alternative drive system for an electric vehicle 31
Slide 32: Expanding ACTech Facilities to Boost Future Growth
Expanding ACTech Facilities to Boost Future Growth Existing plant to be dedicated to 3DP and Casting New plant to be dedicated to CNC and QC 3D printers for sandmolds and cores Printed molds assembly CNC hall 32